In the cohort of decompensated cirrhosis patients, GB1211 was reported to have good tolerability and reduced the levels of the liver injury-related markers ALT, AST, and GGT, indicating that the drug can be used for liver function impairment in the future [204]. The gene discussed is GPT; the disease is Cirrhosis.